HK1067631A1 - Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i) - Google Patents

Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i)

Info

Publication number
HK1067631A1
HK1067631A1 HK05100089.7A HK05100089A HK1067631A1 HK 1067631 A1 HK1067631 A1 HK 1067631A1 HK 05100089 A HK05100089 A HK 05100089A HK 1067631 A1 HK1067631 A1 HK 1067631A1
Authority
HK
Hong Kong
Prior art keywords
insuline
igf
modulators
receptor
growth factor
Prior art date
Application number
HK05100089.7A
Other languages
English (en)
Inventor
Bernard Barlaam
Andrew Pape
Andrew Thomas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1067631A1 publication Critical patent/HK1067631A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HK05100089.7A 2001-12-07 2005-01-06 Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i) HK1067631A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0104140A SE0104140D0 (sv) 2001-12-07 2001-12-07 Novel Compounds
PCT/SE2002/002221 WO2003048133A1 (en) 2001-12-07 2002-12-03 Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i)

Publications (1)

Publication Number Publication Date
HK1067631A1 true HK1067631A1 (en) 2005-04-15

Family

ID=20286257

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05100089.7A HK1067631A1 (en) 2001-12-07 2005-01-06 Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i)

Country Status (33)

Country Link
US (3) US7521453B2 (hu)
EP (1) EP1456182B1 (hu)
JP (1) JP4347051B2 (hu)
KR (1) KR100930558B1 (hu)
CN (1) CN1289486C (hu)
AR (1) AR037736A1 (hu)
AT (1) ATE425150T1 (hu)
AU (1) AU2002365864B2 (hu)
BR (1) BR0214605A (hu)
CA (1) CA2467838C (hu)
CO (1) CO5590919A2 (hu)
CY (1) CY1109101T1 (hu)
DE (1) DE60231542D1 (hu)
DK (1) DK1456182T3 (hu)
EG (1) EG24930A (hu)
ES (1) ES2323125T3 (hu)
HK (1) HK1067631A1 (hu)
HU (1) HUP0401855A3 (hu)
IL (2) IL162376A0 (hu)
IS (1) IS7294A (hu)
MX (1) MXPA04005347A (hu)
MY (1) MY135705A (hu)
NO (1) NO327502B1 (hu)
NZ (1) NZ533130A (hu)
PL (1) PL369528A1 (hu)
PT (1) PT1456182E (hu)
RU (1) RU2317291C2 (hu)
SE (1) SE0104140D0 (hu)
SI (1) SI1456182T1 (hu)
TW (1) TWI324152B (hu)
UA (1) UA78259C2 (hu)
WO (1) WO2003048133A1 (hu)
ZA (1) ZA200404223B (hu)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2445208T3 (es) 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
KR101201603B1 (ko) 2003-07-30 2012-11-14 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방에 사용하기 위한2,4-피리미딘디아민 화합물
EP1663242B1 (en) * 2003-08-07 2011-04-27 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
CN1898240B (zh) * 2003-10-15 2011-08-03 Osi制药公司 咪唑并吡嗪类酪氨酸激酶抑制剂
EP1678169B1 (en) 2003-10-17 2009-07-22 Astrazeneca AB 4-(pyrazol-3-ylamino)pyrimidine derivatives for use in the treatment of cancer
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
ES2299825T3 (es) * 2004-03-12 2008-06-01 Analytecon S.A. Derivados de tetrahidroisoquinoleino y de tetrahidrobenzazepina utilizados como inhibidores de igf-1r.
US7973061B2 (en) * 2004-03-31 2011-07-05 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
BRPI0509576A (pt) 2004-04-02 2007-05-29 Osi Pharm Inc composto, método de tratamento de um paciente tendo uma condição que é mediada pela atividade de proteìna quinase, e, composição farmacêutica
DE102004022897A1 (de) * 2004-05-10 2005-12-08 Bayer Cropscience Ag Azinyl-imidazoazine
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
EP1814878B1 (en) 2004-11-24 2012-01-04 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
JP5208516B2 (ja) * 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
ATE451381T1 (de) 2005-01-19 2009-12-15 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
PL1846394T3 (pl) * 2005-02-04 2012-04-30 Astrazeneca Ab Pochodne pirazoliloaminopirydyny użyteczne jako inhibitory kinazy
KR101362621B1 (ko) 2005-02-16 2014-02-13 아스트라제네카 아베 화합물
GB0507347D0 (en) * 2005-04-12 2005-05-18 Astrazeneca Ab Chemical compounds
WO2006115452A1 (en) * 2005-04-27 2006-11-02 Astrazeneca Ab Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
AU2006248780B2 (en) * 2005-05-16 2010-06-03 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
AU2006283121A1 (en) 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof
ES2374450T3 (es) 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
PT1945631E (pt) * 2005-10-28 2012-10-15 Astrazeneca Ab Derivados de 4-(3-aminopirazole)pirimidina para utilização como inibidores da tirosina-cinase no tratamento do cancro
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
DK2032155T3 (en) * 2006-06-09 2015-03-02 Novartis Ag Stabilized insulin-like growth factor polypeptides
CA2655315A1 (en) * 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-aminoalkyleneaminopyrimidines
EP2044063A1 (en) * 2006-06-30 2009-04-08 Astra Zeneca AB Pyrimidine derivatives useful in the treatment of cancer
US8222256B2 (en) * 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
EP2155742A1 (en) * 2007-04-18 2010-02-24 AstraZeneca AB 5-aminopyrazol-3-yl-3h-imidazo [4,5-b]pyridine derivatives and their use for the treatment of cancer
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
EP2152702B1 (en) * 2007-05-04 2011-08-24 AstraZeneca AB Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer
US8178091B2 (en) 2007-05-21 2012-05-15 University Of Washington Compositions and methods for the treatment of respiratory disorders
WO2009019518A1 (en) * 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
WO2009091939A1 (en) * 2008-01-18 2009-07-23 Osi Pharmaceuticals, Inc. Imidazopyrazinol derivatives for the treatment of cancers
JP2011520970A (ja) * 2008-05-19 2011-07-21 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換されたイミダゾピラジン類およびイミダゾトリアジン類
WO2009150462A1 (en) * 2008-06-11 2009-12-17 Astrazeneca Ab Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
DE102008041214A1 (de) 2008-08-13 2010-02-18 Bayer Cropscience Ag N-substituierte Azinylakyl-azincarboxamide und deren Analoge
RU2011116928A (ru) * 2008-09-30 2012-11-20 Астразенека Аб (Se) Гетероциклические ингибиторы jак киназы
JP2012518657A (ja) 2009-02-25 2012-08-16 オーエスアイ・ファーマシューティカルズ，エルエルシー 併用抗癌治療
US20110171124A1 (en) 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
CA2752826A1 (en) 2009-04-20 2010-10-28 OSI Pharmaceuticals, LLC Preparation of c-pyrazine-methylamines
JP2012526138A (ja) * 2009-05-07 2012-10-25 オーエスアイ・ファーマシューティカルズ，エルエルシー 副腎皮質癌を治療するためのｏｓｉ−９０６の使用
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
EP2519826A2 (en) 2010-03-03 2012-11-07 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2011223655A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2011112666A1 (en) 2010-03-09 2011-09-15 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
BR112012023551A2 (pt) 2010-03-18 2015-09-15 Bayer Ip Gmbh aril e hetaril sulfonamidas como agentes ativos contra estresse abiótico em plantas
US8927547B2 (en) 2010-05-21 2015-01-06 Noviga Research Ab Pyrimidine derivatives
US8546443B2 (en) * 2010-12-21 2013-10-01 Boehringer Ingelheim International Gmbh Benzylic oxindole pyrimidines
EP2671082B1 (en) 2011-02-02 2020-01-15 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012127032A1 (en) 2011-03-24 2012-09-27 Chemilia Ab Novel pyrimidine derivatives
US9096691B2 (en) 2011-04-13 2015-08-04 Eastman Chemical Company Cellulose ester optical films
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
EP2776042B1 (en) 2011-11-11 2019-03-20 Duke University Combination drug therapy for the treatment of solid tumors
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
US9834575B2 (en) 2013-02-26 2017-12-05 Triact Therapeutics, Inc. Cancer therapy
CA2923667A1 (en) 2013-09-09 2015-03-12 Triact Therapeutics, Inc. Cancer therapy
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
CN115124475B (zh) * 2022-07-11 2023-11-10 贵阳学院 一种嘧啶衍生物及其制备方法和用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1417402A (en) * 1972-03-30 1975-12-10 Boots Co Ltd Pharmacologically active anilinobenzothiazoles
DE2426180A1 (de) 1974-05-29 1975-12-18 Bayer Ag Verfahren zum faerben von polyurethankunststoffen
US4485284A (en) * 1982-01-11 1984-11-27 Advanced Moisture Technology, Inc. Apparatus and process for microwave moisture analysis
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CA2104053C (en) * 1992-08-31 1999-04-13 Miguel A. Cacho Automated fluid bed process
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
AU726058B2 (en) 1995-09-01 2000-10-26 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
WO1998044341A1 (de) * 1997-03-27 1998-10-08 Glatt Gmbh Verfahren zum überwachen und/oder steuern und regeln eines granulations-, agglomerations-, instantisierungs-, coating- und trocknungsprozesses in einer wirbelschicht oder einer bewegten schüttung durch bestimmung der produktfeuchte sowie lufttechnischer apparat zur durchführung des verfahrens
US6247246B1 (en) * 1998-05-27 2001-06-19 Denver Instrument Company Microwave moisture analyzer: apparatus and method
DE69933680T2 (de) 1998-08-29 2007-08-23 Astrazeneca Ab Pyrimidine verbindungen
BRPI9915552B8 (pt) 1998-11-10 2021-05-25 Janssen Pharmaceutica Nv pirimidinas inibidoras da reprodução do hiv
WO2000035455A1 (en) 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
DE19917785A1 (de) 1999-04-20 2000-10-26 Bayer Ag 2,4-Diamino-pyrimidin-Derivate
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
SK285240B6 (sk) * 1999-09-24 2006-09-07 Janssen Pharmaceutica N. V. Antivírusové prostriedky
US6455525B1 (en) * 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
CN1429222A (zh) 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
DK1282607T3 (en) * 2000-05-08 2016-02-01 Janssen Pharmaceutica Nv Prodrugs of HIV replication inhibiting pyrimidines
US6613776B2 (en) * 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2422371C (en) * 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20030105090A1 (en) * 2000-12-21 2003-06-05 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
ATE392421T1 (de) * 2001-08-03 2008-05-15 Vertex Pharma Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
CA2456187A1 (en) * 2001-08-03 2003-02-13 Qing Tang Pyrazole-derived kinase inhibitors and uses thereof
US6747461B2 (en) * 2001-10-25 2004-06-08 Pioneer Hi-Bred International, Inc. Apparatus and method for monitoring drying of an agricultural porous medium such as grain or seed
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
PT1812440E (pt) * 2004-11-04 2011-01-25 Vertex Pharma Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases
KR101362621B1 (ko) * 2005-02-16 2014-02-13 아스트라제네카 아베 화합물
BRPI0619708A2 (pt) * 2005-11-03 2011-10-11 Vertex Pharma composto, composição, método para inibir a atividade da proteìna aurora quinase numa amostra biológica, método para tratar distúrbio proliferativo e método para tratar cáncer
EP2044063A1 (en) * 2006-06-30 2009-04-08 Astra Zeneca AB Pyrimidine derivatives useful in the treatment of cancer
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use
TW200823196A (en) * 2006-11-01 2008-06-01 Astrazeneca Ab New use

Also Published As

Publication number Publication date
KR20050044698A (ko) 2005-05-12
MXPA04005347A (es) 2004-09-27
PT1456182E (pt) 2009-05-26
WO2003048133A1 (en) 2003-06-12
MY135705A (en) 2008-06-30
IL162376A0 (en) 2005-11-20
US20120095011A1 (en) 2012-04-19
AR037736A1 (es) 2004-12-01
HUP0401855A3 (en) 2008-06-30
US20050054638A1 (en) 2005-03-10
DE60231542D1 (de) 2009-04-23
HUP0401855A2 (hu) 2004-12-28
ATE425150T1 (de) 2009-03-15
US7521453B2 (en) 2009-04-21
SE0104140D0 (sv) 2001-12-07
EP1456182B1 (en) 2009-03-11
PL369528A1 (en) 2005-05-02
DK1456182T3 (da) 2009-06-29
EP1456182A1 (en) 2004-09-15
JP2005515998A (ja) 2005-06-02
CN1617858A (zh) 2005-05-18
CA2467838A1 (en) 2003-06-12
NZ533130A (en) 2006-11-30
CO5590919A2 (es) 2005-12-30
CN1289486C (zh) 2006-12-13
US20090131463A1 (en) 2009-05-21
RU2317291C2 (ru) 2008-02-20
AU2002365864B2 (en) 2007-08-30
CY1109101T1 (el) 2014-07-02
KR100930558B1 (ko) 2009-12-09
BR0214605A (pt) 2004-09-14
CA2467838C (en) 2010-10-12
RU2004121029A (ru) 2006-01-10
SI1456182T1 (sl) 2009-08-31
IL162376A (en) 2011-07-31
IS7294A (is) 2004-06-03
ES2323125T3 (es) 2009-07-07
ZA200404223B (en) 2005-08-29
UA78259C2 (en) 2007-03-15
NO20042872L (no) 2004-07-06
EG24930A (en) 2011-01-11
AU2002365864A1 (en) 2003-06-17
TW200409634A (en) 2004-06-16
TWI324152B (en) 2010-05-01
NO327502B1 (no) 2009-07-27
JP4347051B2 (ja) 2009-10-21

Similar Documents

Publication Publication Date Title
EG24930A (en) Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (IGF-I)
LT1551511T (lt) Heterocikliniai aromatiniai junginiai, naudingi kaip augimo hormonų sekrecijos stimuliatoriai
IL159741A0 (en) Preparation of aminopyrimidine compounds
HK1135382A1 (en) Substituted pyridinones as modulators of p38 map kinase
IL162189A0 (en) Pyrimidine compounds
GB0212394D0 (en) Single crystal seed
AU2003269885A1 (en) Antisense modulation of g protein-coupled receptor kinase 6 expression
AU2002359574A1 (en) Antisense modulation of g protein-coupled receptor etbr-lp-2 expression
HUP0303159A3 (en) Crystal of pyrimidine nucleoside derivative
AU2002230164A1 (en) Crystal of pyrimidine nucleoside derivative
AU2002359160A1 (en) PIPAZOLO (1,5-a) PYRIMIDINE DERIVATIVES AS MODULATORS OF PPAR
AU2002314182A1 (en) Cortistatin analogs capable of binding selectively to growth hormone secretagogue receptors
GB0112803D0 (en) Pyrimidine derivatives
AU2003201079A1 (en) Improved communication of tv-anytime crids
GB0112809D0 (en) Pyrimidine derivatives
GB0119475D0 (en) Pyrimidine derivatives
GB0112808D0 (en) Pyrimidine derivatives
GB0112807D0 (en) Pyrimidine derivatives
GB0112804D0 (en) Pyrimidine derivatives
AU2002247732A1 (en) Substituted pyrimidinone derivatives as ligands of integrin receptors
GB0129479D0 (en) Correction of data for imaging
AU2002251664A1 (en) Use of npy y2 receptor antagonists

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20131203